Golimumab Effective in non-radiographic Axial Spondyloarthritis Save
The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA). After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein GLM patients continued on GLM (GLM/GLM) and PBO treated patients were then given GLM (PBO/GLM).
Between weeks 16–52 in OLE in both GLM/GLM and PBO/GLM groups improved their efficacy outcomes from weeks 16 to 52:
- ASAS 20: GLM/GLM group went from 71.1% to 83.9% and PBO/GLM improved from 40.0% to 75.0%
- ASAS40: GLM/GLM group went from 56.7% to 76.3% and PBO/GLM improved from 23.0% to 59.4%,
Adverse events were lower in the GLM/GLM vs PBO/GLM groups (41.9% and 54.2%).
GLM was well tolerated and provided substantial long-term benefits to patients with nr-axSpA.